First, our result showed that patients with SFRP2 hypermethylation or co-hypermethylation of SFRP1 and SFRP2 had a lower risk of death in groups of ≥45 years old, male, colon cancer and TNM staging III-IV in traditional univariate and multivariate Cox. This evidence concerns the gene SFRP2 and malignant colon neoplasm.